Deckers Brands has raised its full-year revenue growth outlook by 15% after delivering record quarterly revenue in Q3 of 2025 ...

Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...

Teva Pharmaceutical Industries Ltd (TEVA) reports a 9% revenue increase, driven by innovative and generics business, despite ...

The global plant-based API market is expected to experience robust growth, with a projected value of USD 30,084.8 million in ...

Deckers Outdoor on Thursday beat third-quarter sales estimates on robust holiday demand for its Hoka running shoes, but an in ...

2025年1月30日，制药公司梯瓦制药（TEVA）成交额为6.14亿美元，在当日美股中排第143名，成交额较昨日减少22.41%，当日成交量为3437.13万。 梯瓦制药（TEVA）于2025年1月30日跌3.78%，报17.84美元，该股过去5个交易日跌18.13%，整个1月跌19.06%，年初至今跌19.06%，过去52周涨47.44%。 *如果公司上市时间少于52周，则52周涨跌幅为上市至今 ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

北京时间2025年01月31日02时31分，梯瓦制药（TEVA.us）股票出现异动，股价大幅下挫5.04%。截至发稿，该股报17.61美元/股，成交量2073.05万股， 换手率 1.83%，振幅5.23%。

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...